Compassionate Psilocybin: Access Programs, Patient Eligibility & Clinical Context
An exploration of compassionate access frameworks for psilocybin — examining who qualifies, how clinicians apply for exemptions, the therapeutic setting requirements, and what patient outcomes data tell us about psilocybin's role beyond clinical trials.
Source Research Papers
Citations in APA 7 format. All studies were sourced from peer-reviewed journals via Google Scholar. Unfamiliar terms? See the plain-language glossary →
de la Salle, S., Kettner, H., Thibault Lévesque, J., Garel, N., Dames, S., Patchett-Marble, R., Rej, S., Gloeckler, S., Erritzoe, D., Carhart-Harris, R., & Greenway, K. T. (2024). Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy. Scientific Reports, 14, 15353. https://doi.org/10.1038/s41598-024-66817-0
26 Canadians who received psilocybin therapy through a special-access program reported real, lasting improvements in their mental health. It wasn't a controlled trial, but it's a valuable look at how the treatment works outside the lab.
Shop Related Spores
Laboratory-grade Psilocybe cubensis spore syringes for microscopy research.